QUANTA-CLOUD-TECHNOLOGY
24.5.2022 06:02:09 CEST | Business Wire | Press release
Quanta Cloud Technology (QCT), a global data center solution provider, today announced new servers that will support the NVIDIA Grace™ CPU Superchip and Grace™ Hopper™ Superchip . QCT is incorporating the NVIDIA Grace™ CPU, striving for the highest performance, memory bandwidth, energy efficiency and configurability that is ready for the modern data center and addresses the most demanding artificial intelligence (AI), high-performance computing (HPC), data analytics, digital twins, cloud gaming, and hyperscale computing applications.
Breakthrough CPU for the Modern Data Center
The NVIDIA Grace CPU Superchip is a breakthrough processor designed for the modern data center, providing the highest performance and twice the memory bandwidth and energy-efficiency compared to today’s leading server processors. The NVIDIA Grace CPU Superchip can be used standalone or with NVIDIA’s industry-leading GPU and BlueField® data processing unit (DPU) building blocks. The Grace Hopper Superchip pairs an NVIDIA Grace CPU with an NVIDIA Hopper architecture-based GPU. The integrated module is designed to serve HPC and giant-scale AI applications. The NVIDIA Grace Hopper Superchip will enable up to 10x higher performance in a variety of configurations for applications running terabytes of data, enabling scientists and researchers to reach unprecedented solutions to the world’s most complex problems.
“As a leading cloud enabler, QCT is committed to being a critical enabler for AI and HPC applications for the modern data center,” said Mike Yang, President of QCT. “We are thrilled to broaden our compute portfolio with the NVIDIA Grace CPU Superchip and Grace Hopper Superchip. As we are seeing a rise in the multitude of AI applications, QCT works closely with NVIDIA to ensure our clients can benefit from the latest and greatest CPU, GPU and networking technologies.”
QCT will add the new NVIDIA Grace CPU Superchip and Grace Hopper Superchip to its extensive server portfolio to deliver unprecedented accelerated computing. Designed to interface with the latest PCIe Gen5 protocol, this will be the fastest communication to enable optimal connectivity with the highest-performing GPUs, and the fastest networking with up to 400 gigabits per second (Gb/s) Ethernet or NVIDIA Quantum-2 400Gb/s InfiniBand with NVIDIA ConnectX®-7 smart network interface cards (SmartNICs) and BlueField-3 DPUs to provide best-in-class acceleration for secure HPC and AI workloads. These new QCT server systems will be released next year and will also support NVIDIA’s computing software stacks, including NVIDIA HPC, NVIDIA AI, Omniverse and NVIDIA RTX.
Follow QCT on Facebook and Twitter to receive the latest news and announcements.
About QCT
QCT is a global data center solution provider that combines the efficiency of hyperscale hardware with infrastructure software from a diversity of industry leaders to solve next-generation data center design and operational challenges. QCT serves cloud service providers, telecoms and enterprises running public, hybrid and private clouds. The parent of QCT is Quanta Computer, Inc., a Fortune Global 500 corporation. www.qct.io
View source version on businesswire.com: https://www.businesswire.com/news/home/20220523005375/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom